story of the week
Individualised Neoantigen Therapy mRNA-4157 (V940) Plus Pembrolizumab vs Pembrolizumab Monotherapy for Resected Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Lancet 2024 Jan 18;[EPub Ahead of Print], JS Weber, MS Carlino, A Khattak, T Meniawy, G Ansstas, MH Taylor, KB Kim, M McKean, GV Long, RJ Sullivan, M Faries, TT Tran, CL Cowey, A Pecora, M Shaheen, J Segar, T Medina, V Atkinson, GT Gibney, JJ Luke, S Thomas, EI Buchbinder, JA Healy, M Huang, M Morrissey, I Feldman, V Sehgal, C Robert-Tissot, P Hou, L Zhu, M Brown, P Aanur, RS Meehan, T ZaksFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.